Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC Prophylaxis for Poor Graft Function in Acute Leukemia Post-Haplo-HSCT
NCT03236220Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acetylcysteine in poor graft function (PGF) and isolated thrombocytopenia, sponsored by Peking University People's Hospital. Primary endpoint: Incidence of poor graft function and prolonged isolated thrombocytopenia. Started Aug 2017; status: completed.
02
Drugs
acetylcysteine
03
Conditions
poor graft function (PGF)isolated thrombocytopenia
Beyond the preview
Go deeper on NCT03236220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236220.